Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity.

Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, Dugast AS, Heizen EL, Ercan A, Choi I, Streeck H, Nigrovic PA, Bailey-Kellogg C, Scanlan C, Alter G.

J Clin Invest. 2013 May;123(5):2183-92. doi: 10.1172/JCI65708. Epub 2013 Apr 8.

2.

Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination.

Mahan AE, Jennewein MF, Suscovich T, Dionne K, Tedesco J, Chung AW, Streeck H, Pau M, Schuitemaker H, Francis D, Fast P, Laufer D, Walker BD, Baden L, Barouch DH, Alter G.

PLoS Pathog. 2016 Mar 16;12(3):e1005456. doi: 10.1371/journal.ppat.1005456. eCollection 2016 Mar. Erratum in: PLoS Pathog. 2016 Jun;12(6):e1005694.

3.

Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H.

J Immunol. 2010 Dec 1;185(11):6876-82. doi: 10.4049/jimmunol.1002600. Epub 2010 Nov 1.

4.

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.

Chung AW, Crispin M, Pritchard L, Robinson H, Gorny MK, Yu X, Bailey-Kellogg C, Ackerman ME, Scanlan C, Zolla-Pazner S, Alter G.

AIDS. 2014 Nov 13;28(17):2523-30. doi: 10.1097/QAD.0000000000000444.

5.

Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16.

Gunn B, Schneider J, Shansab M, Bastian AR, Fahrbach K, Smith A 4th, Mahan A, Karim M, Licht A, Zvonar I, Tedesco J, Anderson M, Chapel A, Suscovich T, Malaspina D, Streeck H, Walker BD, Kim A, Lauer G, Altfeld M, Pillai S, Szleifer I, Kelleher NL, Kiser PF, Hope TJ, Alter G.

Mucosal Immunol. 2016 Nov;9(6):1549-1558. doi: 10.1038/mi.2016.8. Epub 2016 Mar 9.

6.

Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Vargas-Inchaustegui DA, Robert-Guroff M.

Curr HIV Res. 2013 Jul;11(5):407-20.

PMID:
24191937
7.

Opportunities to exploit non-neutralizing HIV-specific antibody activity.

Ackerman ME, Alter G.

Curr HIV Res. 2013 Jul;11(5):365-77. Review.

8.

Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments.

Jez J, Antes B, Castilho A, Kainer M, Wiederkum S, Grass J, Rüker F, Woisetschläger M, Steinkellner H.

J Biol Chem. 2012 Jul 13;287(29):24313-9. doi: 10.1074/jbc.M112.360701. Epub 2012 May 15.

9.

Fc receptor but not complement binding is important in antibody protection against HIV.

Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR.

Nature. 2007 Sep 6;449(7158):101-4.

PMID:
17805298
10.

Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, Ackerman ME, Streeck H, Klasse PJ, Moore JP, Alter G.

Eur J Immunol. 2014 Oct;44(10):2925-37. doi: 10.1002/eji.201344305. Epub 2014 Aug 11.

11.

Role of Fc-mediated antibody function in protective immunity against HIV-1.

Lewis GK.

Immunology. 2014 May;142(1):46-57. doi: 10.1111/imm.12232. Review.

12.

Editorial: Fc receptor-mediated effector functions in the humoral control of HIV-1 infection.

DeVico A.

Curr HIV Res. 2013 Jul;11(5):343-4. No abstract available.

PMID:
24191941
13.

Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.

Sips M, Krykbaeva M, Diefenbach TJ, Ghebremichael M, Bowman BA, Dugast AS, Boesch AW, Streeck H, Kwon DS, Ackerman ME, Suscovich TJ, Brouckaert P, Schacker TW, Alter G.

Mucosal Immunol. 2016 Nov;9(6):1584-1595. doi: 10.1038/mi.2016.12. Epub 2016 Feb 17.

14.

Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.

Huang Y, Ferrari G, Alter G, Forthal DN, Kappes JC, Lewis GK, Love JC, Borate B, Harris L, Greene K, Gao H, Phan TB, Landucci G, Goods BA, Dowell KG, Cheng HD, Bailey-Kellogg C, Montefiori DC, Ackerman ME.

J Immunol. 2016 Dec 15;197(12):4603-4612. Epub 2016 Nov 9.

15.

Terminal sugars of Fc glycans influence antibody effector functions of IgGs.

Raju TS.

Curr Opin Immunol. 2008 Aug;20(4):471-8. doi: 10.1016/j.coi.2008.06.007. Epub 2008 Jul 17. Review.

PMID:
18606225
16.

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.

Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P.

J Mol Biol. 2003 Jan 31;325(5):979-89.

PMID:
12527303
17.

Development of stage-dependent glycans on the Fc domains of IgG antibodies of ALS animals.

Edri-Brami M, Sharoni H, Hayoun D, Skutelsky L, Nemirovsky A, Porgador A, Lichtenstein RG.

Exp Neurol. 2015 May;267:95-106. doi: 10.1016/j.expneurol.2015.02.023. Epub 2015 Feb 26.

PMID:
25725350
19.

Regulation of antibody effector functions through IgG Fc N-glycosylation.

Quast I, Peschke B, Lünemann JD.

Cell Mol Life Sci. 2017 Mar;74(5):837-847. doi: 10.1007/s00018-016-2366-z. Epub 2016 Sep 17. Review.

PMID:
27639381
20.

Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

Forthal DN, Landucci G, Phan TB, Becerra J.

J Virol. 2005 Feb;79(4):2042-9. Erratum in: J Virol. 2005 Apr;79(7):4555.

Supplemental Content

Support Center